Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, ...

On this weeks episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why ...

Servant leadership means putting people first because results follow people, not the other way around, writes Boehringer ...

Five of the best-known contract sales providers have changed owners, leaders, or reporting structure since 2022. Contracts should reflect those changes, writes Hoyt Gong.

On this weeks episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s.

Co-development is an established concept. The practical question is how early its logic should shape candidate selection, development planning, and portfolio governance. Combination therapy is routine ...

In pharma, an oncology drug approval is a significant milestone. I have spent enough time in this space to know that it is also the moment where a different, less visible problem begins. The community ...

The choice between Nasdaq and the New York Stock Exchange (or NYSE American) has traditionally been made once – and rarely revisited. Market perception, investor demographics, analyst coverage, ...

Most breakthrough medicines begin in academia, are developed further in biotechnology companies and, if successful, eventually end up in the hands of large pharmaceutical companies capable of bringing ...

Over the weekend, the Financial Times reported that AstraZeneca and Bristol Myers Squibb were exploring what would have been the largest pharmaceutical merger in history. The news sent AstraZeneca's ...

For decades, the Silicon Valley playbook has dominated the narrative of innovation: a brilliant founder hacks together a minimum viable product in a garage, pitches a traditional venture capital (VC) ...

Life sciences companies operate at the leading edge of innovation, structuring high-value licensing, development, and outsourcing arrangements in a highly regulated environment. A persistent and often ...